News
Feed
Events
Feed
News
+ Events
Feed

Vita 34 AG

  • ISIN DE000A0BL849
  • Country Deutschland

Company profile

Vita 34 was founded in Leipzig in 1997 and is today by far the leading cell bank in Europe and the third largest worldwide. As Europe’s first private cord blood bank and a pioneer in cell banking, the company has since offered collection logistics, processing and storage of stem cells from umbilical cord blood, umbilical cord tissue and other postnatal tissues as a full-service cryopreservation provider. Based on the expansion of the business model that took place after the merger with PBKM, the company intends to invest in the areas of Cell and Gene therapies and CDMO. The body’s own cells are a valuable starting material for medical cell therapy and are kept alive in the vapors of liquid nitrogen. Customers from around 50 countries have already ensured the health of their families with more than 930,000 units of stored biological material at Vita 34.

Management

Jakub Baran
Jakub Baran CEO of Vita 34 AG
Jakub Baran
Jakub Baran CEO of Vita 34 AG

Jakub Baran graduated in 1995 from the Wrocław University of Technology as a Master of Science and Engineer in Electronics, majoring in Telecommunications – Digital Signal Processing. He started his professional career at Hewlett-Packard as Staff Engineer and then later as VAB Developer, PC Sales Representative, Senior Account Manager. He joined IBM in 2003 as Sales Director for Telecommunication Market. While working in the IT industry, Jakub has been very successful in sales always meeting or exceeding the number of goals. In 2005 he decided to leave IBM to join PBKM board – the company established in 2002 where he was one of five founders. At PBKM he was initially responsible for sales, operations, finance and business development as well. In 2006 Jakub Baran initiated international expansion of PBKM. He was responsible personally for ~20 successful M&A-nature transactions in: Hungary, Spain, Romania, Poland, Turkey, Latvia, Switzerland, Czech Rep., Slovakia, Portugal and the UK. In the meantime in 2009 he was appointed as CEO of PBKM. He led successful IPO of PBKM at WSE in 2015. Under his management PBKM (operating under umbrella of FamiCord Group) reached position no 1 in Europe with ca 40% market share and no 4 in the world in family stem cell banking sector. During his career at PBKM Jakub gather a lot of expertise in various areas like building international capital group, creation and implementation of strategy, preparation and execution of company budgets, deep experience in mergers and acquisitions, practical knowledge of law in the area of commercial and investment agreements, practical knowledge of financial reporting and experience in managing international teams/companies of 500+ people. Jakub was an initiator and spiritus movens of the merger between PBKM and Vita34. Jakub finished couple of dozens of various professional trainings across Europe (including programs organized by INSEAD and IESE). He is also co-author of a dozen of articles on stem cells applications and technology. Privately a fan of SF literature, strategic games and economy. He stays in informal partnership and has one child.


 

Tomasz Baran
Tomasz Baran CCO of Vita 34 AG
Tomasz Baran
Tomasz Baran CCO of Vita 34 AG
In 1997, Tomasz Baran completed medical education with MD title from Medical University in Lublin, Poland. Since then he has been working on several positions in pharma industry in Poland. His duties covered sales, marketing, business development and pharmacovigilance. In 2008, Tomasz completed Executive MBA programme by Quebec University in Montreal. During 13 years of work for domestic and international companies (Pliva, AstraZeneca, Stiefel and GSK) he has gained an expertise in several therapeutic areas – including oncology, cardiology, dermatology and aesthetic medicine. In 2010, he joined Polski Bank Komórek Macierzystych S.A. (PBKM) in a role of Sales &Marketing Director for domestic market. Then the role expanded to cover also international markets, where PBKM operates under FamiCord brand. In 2012, Tomasz joined the Management Board, and since 2020 he serves as Executive Vice-president. In recent years, he attended dedicated international executive training programmes done by IESE. He regularly attends and contributes as speaker on stem cell conferences in Europe and in the US. Additionally to developing of family cord blood bank activity Tomasz contributed to strategic projects of FamiCord group, such us stem cell based Advanced Therapy Product (ATMP) manufacturing and novel CAR-T technology in licensing (as CEO of daughter company – FamiCordTx).

IR contact

Vita 34 AG

Vita 34 AG

Deutscher Platz 5
04103 Leipzig
Deutschland
Tel.: +49 (0)341 48792-40
Fax: +49 (0)341 48792-39
Mail:ir@vita34.de